
Ex-Trump surgeon general says RFK Jr.'s halt to mRNA vaccine research threatens "most promising areas of modern medicine"
Kennedy announced last week that the administration was canceling 22 mRNA vaccine development projects, saying the vaccines "fail to protect effectively against upper respiratory infections like COVID and flu." The projects were funded through the Biomedical Advanced Research and Development Authority, or BARDA. Kennedy said the funds would be shifted toward "safer, broader vaccine platforms that remain effective even as viruses mutate."
Adams, who appeared Sunday on "Face the Nation with Margaret Brennan," said Kennedy's assertions about the efficacy of mRNA vaccines are "simply not true."
"We know that by the most conservative estimates, upward of 2 million lives have been saved because of mRNA technology," Adams said. "It helped us develop COVID-19 vaccines in record time. And it's, quite frankly, President Trump's greatest achievement."
The mRNA technology was central to Operation Warp Speed, a public-private partnership aimed at quickly developing COVID-19 vaccines at the onset of the coronavirus pandemic near the end of Mr. Trump's first term. If the U.S. had relied on older vaccine technology, it could have taken an extra 18 to 24 months to develop COVID-19 shots, Adams said.
Asked about Kennedy's move by CBS News earlier this week, Mr. Trump said, "Operation Warp Speed was, whether you're Republican or a Democrat, considered one of the most incredible things ever done in this country," while noting that he had upcoming meetings on the topic.
Adams, who was involved in the Operation Warp Speed effort, said it's "fascinating" to him that, as Mr. Trump and his allies discuss whether he deserves a Nobel Prize, "the thing that he should be considered for the Nobel Prize for, his health secretary is trying to undermine."
The former surgeon general outlined that mRNA is a type of natural molecule that's present in the body and operates like a "recipe card that tells your body how to make a protein." He said the technology "helps us develop vaccines and new treatments" in other areas — from cancers to HIV to the flu and the Zika virus.
"These are advances that are not going to happen now," Adams said. "People are going to die because we're cutting short funding for this technology."
Adams also criticized Kennedy for his response to a shooting outside Centers for Disease Control and Prevention buildings in Atlanta on Friday. Investigators have been looking into possible motives, including the possibility that the suspect believed he was sick as a result of the COVID vaccine, multiple sources told CBS News.
"How you respond to a crisis defines a leader. Quite frankly, Secretary Kennedy has failed in his first major test in this regard," Adams said, accusing Kennedy of issuing "tepid response" to the shooting, while adding, "and that's not even considering how his inflammatory rhetoric in the past have actually contributed to a lot of what's been going on."
In a statement Friday, Kennedy said, "No one should face violence while working to protect the health of others." But Adams argued Kennedy has not "unequivocally condemned the violence."
"There's an out there," Adams said. "If you don't believe that people are working to protect the public, then that means it's okay to commit violence, at least in some people's eyes."
The former surgeon general said people at the CDC were calling him after the shooting asking him to make a public statement "because they felt under attack."
"They didn't know if this was going to continue," Adams said. "They were scared, and they wanted someone, someone who they felt had a public voice, to go out there and say, 'This is wrong. Violence is wrong.'"
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
6 minutes ago
- Yahoo
Vermont Secretary of State Sarah Copeland-Hanzas announces 2026 re-election campaign
Vermont's incumbent Secretary of State announced the bid in an email to supporters Monday. Solve the daily Crossword
Yahoo
6 minutes ago
- Yahoo
Tennis star Monica Seles diagnosed with myasthenia gravis. What is it?
Tennis legend Monica Seles is opening up about her journey with myasthenia gravis, a neuromuscular autoimmune disease she was diagnosed with three years ago. In a recent interview with The Associated Press, Seles, 51, said she chose to share her diagnosis ahead of the U.S. Open later this month to raise awareness about the disease, also known as MG. Myasthenia gravis affects about 20 out of every 100,000 people in the world, according to the Cleveland Clinic. "The actual number may be higher, as some people with mild cases may not know they have the condition," the clinic notes. "In the United States, there are approximately 60,000 people affected by myasthenia gravis at any given time." Seles, whose career included nine Grand Slam titles and a place in the International Tennis Hall of Fame, said it took time to process the diagnosis. "It took me quite some time to really absorb it, speak openly about it, because it's a difficult one. It affects my day-to-day life quite a lot," she told the AP. Myasthenia gravis symptoms Seles said she was referred to a neurologist after noticing symptoms such as double vision and weakness in her arms and legs. "I would be playing with some kids or family members, and I would miss a ball. I was like, 'Yeah, I see two balls.' These are obviously symptoms that you can't ignore," Seles said, adding even blowing out her hair "became very difficult." In addition to eyes, arms and legs, myasthenia gravis can target muscles in the face and neck, according to the Cleveland Clinic, with symptoms that include: Muscle weakness and fatigueDroopy eyelidsBlurry or double visionLimited facial expressionsDifficulty speaking, swallowing or chewingTrouble walking Muscles usually get weaker when someone is active and strengthen when they rest, the clinic adds. What causes myasthenia gravis? The autoimmune form of MG happens when the body's immune system mistakenly attacks itself, the Cleveland Clinic says. It is unclear why this happens. "Studies suggest that certain immune system cells in your thymus gland have trouble identifying what's a threat to your body (like bacteria or viruses) versus healthy components," the clinic adds. While the disease can affect people of any age, the Mayo Clinic notes it is more common in women younger than 40 and in men older than 60. Myasthenia gravis treatment There is no cure for myasthenia gravis, although treatment can help with symptoms. Treatment options include medications, thymus gland removal surgery, lifestyle changes and more, according to the National Institute of Neurological Disorders and Stroke. "Some cases of myasthenia gravis may go into remission, either temporarily or permanently and muscle weakness may disappear completely," the institute added. Trump says he's placing D.C. police under federal control, deploying National Guard Jamie Lee Curtis: The 60 Minutes Interview What will National Guard troops do in Washington, D.C.? Solve the daily Crossword
Yahoo
6 minutes ago
- Yahoo
If You'd Invested $1,000 in Viking Therapeutics 3 Years Ago, Here's How Much You'd Have Today
Key Points Weight loss drugs are big news, and Viking has one in development in both injectable and oral form. Investors are eagerly awaiting trial results later this year. 10 stocks we like better than Viking Therapeutics › Viking Therapeutics (NASDAQ: VKTX) investors have seen a handsome return over the past three years, and this demonstrates that the real battle over biopharmaceutical stocks is won in the lab and clinical trials. Viking Therapeutics doesn't have a commercial product on the market yet and has never generated a dollar in revenue. Yet, it's made many investors wealthy. One thousand dollars invested three years ago is now worth an incredible $10,640 as of Aug. 11. Viking Therapeutics: The best may be yet to come The excitement around the stock centers on its lead development compound, VK2735. It's a GLP-1/GIP dual agonist for the treatment of obesity. Vikings VK2735 is following in the footsteps of Eli Lilly's GLP-1/GIP dual agonist tirzepatide (branded as Zepbound), and investors are hoping VK2735 can achieve similar levels of success. Where is this promising drug now VK2735 is in phase 3 trials in subcutaneous (injection) form, with results probably not due until 2027, and, arguably more excitingly, it's in phase 2 trials in an oral form. The latter has obvious benefits of convenience and comfort for patients, and management expects to report on the phase 2 trial this year. Investors have high hopes, as the phase 2 subcutaneous trial resulted in up to 88% of patients experiencing more than 10% weight loss. The phase 1 trials in oral form were also impressive (remember that phase 1 trials are fundamentally exploratory and often aim to understand safety and tolerability), with a mean weight loss of 8.2% after 28 days of dosing. These results are enough to encourage Viking investors that VK2735 could prove to be a hugely successful compound, and the results of the latest tests of the oral form are eagerly anticipated, not least by potential larger pharmaceutical companies that may try to buy the company and take VK2735 (oral) through phase 3. Should you invest $1,000 in Viking Therapeutics right now? Before you buy stock in Viking Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Viking Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $653,427!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,119,863!* Now, it's worth noting Stock Advisor's total average return is 1,060% — a market-crushing outperformance compared to 182% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 11, 2025 Lee Samaha has no position in any of the stocks mentioned. The Motley Fool recommends Viking Therapeutics. The Motley Fool has a disclosure policy. If You'd Invested $1,000 in Viking Therapeutics 3 Years Ago, Here's How Much You'd Have Today was originally published by The Motley Fool